Nurix appoints drug commercialization veteran Anil Kapur to board of directors

Nurix Therapeutics, Inc.

Appointed Anil Kapur as Class I director effective Oct 15, 2024, with term expiring at 2027 annual meeting.
Mr. Kapur brings 25+ years of pharma exec experience, including launching Imbruvica and Darzalex.
Received initial stock option for 50,000 shares vesting monthly over 3 years, plus annual equity awards.
Appointment aims to support plan to advance NX-5948 into pivotal testing in 2025 and prepare for commercialization.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anil Kapur

Director

NRIX · Nurix Therapeutics, Inc.

Effective: 2024-10-15
Filed: October 16, 2024, 7:59 PM ET

On October 15, 2024, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Anil Kapur to serve as a director of the Company and as a member of the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anil Kapur was appointed as Director at Nurix Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 15, 2024, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Anil Kapur to serve as a director of the Company and as a member of the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.

View on SEC.gov

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001549595-24-000138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.